Effect of nateglinide on the incidence of diabetes and cardiovascular events.

BACKGROUND: The ability of short-acting insulin secretagogues to reduce the risk of diabetes or cardiovascular events in people with impaired glucose tolerance is unknown. METHODS: In a double-blind, randomized clinical trial, we assigned 9306 participants with impaired glucose tolerance and either...

Descripción completa

Detalles Bibliográficos
Autores principales: Holman, R, Haffner, S, McMurray, J, Bethel, M, Holzhauer, B, Hua, T, Belenkov, Y, Boolell, M, Buse, J, Buckley, B, Chacra, A, Chiang, F, Charbonnel, B, Chow, C, Davies, M, Deedwania, P, Diem, P, Einhorn, D, Fonseca, V, Fulcher, G, Gaciong, Z, Gaztambide, S, Giles, T, Horton, E, Ilkova, H
Formato: Journal article
Lenguaje:English
Publicado: 2010